HC Wainwright Reiterates “$3.00” Price Target for Cancer Genetics (CGIX)

HC Wainwright set a $3.00 target price on Cancer Genetics (NASDAQ:CGIX) in a research note issued to investors on Tuesday. The brokerage currently has a buy rating on the medical research company’s stock.

Several other equities analysts have also recently commented on CGIX. Zacks Investment Research raised shares of Cancer Genetics from a sell rating to a hold rating in a research note on Thursday, May 3rd. ValuEngine raised shares of Cancer Genetics from a sell rating to a hold rating in a research note on Wednesday, May 2nd. Dawson James cut shares of Cancer Genetics from a buy rating to a neutral rating in a research note on Friday, April 6th. Finally, Maxim Group cut shares of Cancer Genetics from a buy rating to a hold rating and set a $6.00 target price on the stock. in a research note on Tuesday, April 3rd. Five research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $4.81.

Cancer Genetics stock opened at $0.96 on Tuesday. The stock has a market cap of $27.19 million, a price-to-earnings ratio of -1.22 and a beta of 1.28. The company has a debt-to-equity ratio of 0.03, a quick ratio of 0.92 and a current ratio of 0.92. Cancer Genetics has a 52 week low of $0.82 and a 52 week high of $4.35.

Cancer Genetics (NASDAQ:CGIX) last released its earnings results on Tuesday, May 15th. The medical research company reported ($0.16) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.03). The company had revenue of $7.67 million for the quarter, compared to analyst estimates of $10.20 million. Cancer Genetics had a negative net margin of 52.87% and a negative return on equity of 77.26%. research analysts forecast that Cancer Genetics will post -0.43 earnings per share for the current year.

An institutional investor recently bought a new position in Cancer Genetics stock. Stonepine Capital Management LLC acquired a new position in Cancer Genetics Inc (NASDAQ:CGIX) during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 1,786,063 shares of the medical research company’s stock, valued at approximately $3,304,000. Cancer Genetics comprises approximately 2.0% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 16th largest holding. Stonepine Capital Management LLC owned about 6.45% of Cancer Genetics at the end of the most recent reporting period. Institutional investors and hedge funds own 17.22% of the company’s stock.

Cancer Genetics Company Profile

Cancer Genetics, Inc develops, commercializes, and provides molecular and biomarker-based tests and services in the United States, India, and China. Its tests enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor, and inform cancer treatment; and enable biotech and pharmaceutical companies involved in oncology trials to select candidate populations and reduce adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics.

Receive News & Ratings for Cancer Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply